Publicações

Overall Survival (Os) in the Imelda Randomized Phase Iii Trial of Maintenance Bevacizumab (Bev) with or Without Capecitabine (Cap) for Her2-Negative Metastatic Breast Cancer (Mbc)

AuthID
P-00G-D2N

Author(s)

Gligorov, J

Bines, J

Alba, E

Mustacchi, G

Cinieri, S

Gupta, V

Pierga, JY

Bozcuk, H

Gaafar, R

Gupta, S

Vivanco, GL

Wang, XJ

Costa, R

Altundag, K

Chmielowska, E

de Ducla, S

Freudensprung, U

Cortes, P

Doval, D

Tipo de Documento

Abstract

Year published

2015

Publicado

in CANCER RESEARCH, ISSN: 0008-5472

Volume: 75, Número: 9, Páginas: P2-17-01-P2-17-01 (2)

Conference

37Th Annual Ctrc-Aacr San Antonio Breast Cancer Symposium, Date: DEC 09-13, 2014, Location: San Antonio, TX, Patrocinadores: CTRC, AACR

Indexing

Wos^®

Crossref^®

Google Scholar^®

Metadata
Fontes

Publication Identifiers

DOI: 10.1158/1538-7445.sabcs14-p2-17-01

Wos: WOS:000356730201241

Source Identifiers

ISSN: 0008-5472

Export Publication Metadata

Lista Marked

Adicionar à lista Marked

Info

At this moment we don't have any links to full text documens.

Overall Survival (Os) in the Imelda Randomized Phase Iii Trial of Maintenance Bevacizumab (Bev) with or Without Capecitabine (Cap) for Her2-Negative Metastatic Breast Cancer (Mbc)

Links Úteis

Ajuda

Autenticação Federada (Clique na imagem)

Overall Survival (Os) in the Imelda Randomized Phase Iii Trial of Maintenance Bevacizumab (Bev) with or Without Capecitabine (Cap) for Her2-Negative Metastatic Breast Cancer (Mbc)

Links Úteis

Ajuda